#United States #AbbVie #North Chicago #Atogepant #Topiramate

New Data on Atogepant in Migraine Prevention

AbbVie has recently disclosed breakthrough findings regarding Atogepant, a medication aimed at preventing migraines. In a Phase III trial, referred to as the TEMPLE trial, Atogepant demonstrated superiority compared to Topiramate, a well-known epilepsy medication, across all evaluated endpoints. This study targeted adult patients with a history of experiencing more than four migraine days per month, showcasing Atogepant's potential to enhance treatment options for those suffering from this debilitating condition.

Overview of the TEMPLE Trial

The TEMPLE trial was a multi-center, randomized, double-blind study designed to assess the tolerability, safety, and efficacy of Atogepant (60 mg taken once daily) against Topiramate at its highest tolerated doses (50, 75, or 100 mg per day). According to Abbvie's report, the key metrics revolving around the discontinuation due to adverse events (AEs) were notably favorable; Atogepant's discontinuation rate stood at 12.1%, compared to 29.6% for Topiramate, resulting in a relative risk of 0.41 (95% CI: 0.28, 0.59; p<0.0001).

Additionally, six secondary endpoints, including significant clinical effectiveness metrics, were also achieved, confirming Atogepant's viability as a preventive migraine treatment. For instance, among those participants, 64.1% in the Atogepant group experienced over a 50% reduction in monthly migraine days, in sharp contrast to the 39.3% in the Topiramate group (p<0.0001).

These results reinforce the role of CGRP inhibitors, like Atogepant, in the field of migraine prevention, aligning with recommendations set forth by organizations such as the American Headache Society and the International Headache Society. Roopal Thakkar, M.D., AbbVie's Executive Vice President of Research and Development, emphasized that these findings contribute to a broader range of therapeutic options and elevate the standard of care for patients.

The Impact of Migraines

Despite the significant burden migraines impose on patients' lives, the condition is often underdiagnosed and inadequately treated. Affecting approximately 14% of the global population, migraines rank as the second leading cause of disability worldwide. The high prevalence rates underscore the urgent need for effective prevention strategies, particularly since existing treatments appear insufficient for over 50% of patients currently on preventive medications.

Dr. Jaclyn Duvall, a neurologist and founder of the Headache Specialists of Oklahoma, noted, “Many patients with migraines struggle to achieve treatment goals, despite the availability of accessible preventive therapies. The TEMPLE trial results highlight both efficacy and tolerability, offering valuable insights into the impacts of treatment adherence in migraine prevention.”

Results Presentation

All findings from the TEMPLE trial will be presented at upcoming medical conferences, providing further insights into Atogepant's efficacy and safety profile, which aligns with previously established safety data from earlier studies.

About Atogepant

Atogepant is an oral CGRP receptor antagonist designed for the preventive treatment of migraines in adults. It works by modulating the pathways involved in migraine pathophysiology. Elsewhere in the world, Atogepant is known as AQUIPTA® in the EU and QULIPTA® in the U.S., Canada, Israel, and Puerto Rico, with approval in over 60 countries.

AbbVie’s Commitment

AbbVie continues to focus on the needs of migraine sufferers by advancing science and fostering collaboration with healthcare providers. Their mission is to eliminate barriers to care, ensuring that migraine patients receive the appropriate treatment to ease the impact of migraines in their daily lives. In the United States, AbbVie is the only company that has developed three types of medications to meet the diverse needs of patients dealing with this exhausting condition.

For more detailed information about the TEMPLE trial, you can visit Clinical Trials.